---
title: "AEON Biopharma (AEON) news: reverse split and offering"
url: "https://aibio.space/companies/aeon-biopharma/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "AEON reverse split, offering and convertible notes news: AEON Biopharma seeks approval for a reverse split of up to 1-for-100. AEON Biopharma, Inc."
---

AEON AEON Biopharma, Inc. AMEX · United States

# AEON Biopharma (AEON) news AEON reverse split, offering and convertible notes news

Listings · 2026-10-26

## [AEON Biopharma seeks approval for a reverse split of up to 1-for-100](https://aibio.space/news/aeon-biopharma-seeks-approval-reverse-split-up-1-100/)

AEON Biopharma asked stockholders to approve a reverse stock split of between 1-for-2 and 1-for-100, to be voted on December 15, 2026. The stock last sold at $0.24 on October 23, and NYSE American's cumulative ratio limit counts the company's 1-for-72 split of February 2025.

## Latest AEON Biopharma news

1. 2026-09-30 Company Updates [AEON says FDA feedback may support a streamlined ABP-450 development path](https://aibio.space/news/aeon-says-fda-feedback-may-support-streamlined-abp-450-development/) AEON Biopharma received official minutes from a Type 2b meeting with the FDA on its BOTOX biosimilar. It plans to file an IND for a comparative pharmacodynamic study in the fourth quarter of 2026.
2. 2026-08-12 Company Updates [AEON reports second-quarter 2026 results and a $15.3 million financing](https://aibio.space/news/aeon-reports-second-quarter-2026-results-15-3-million-financing/) AEON Biopharma reported $3.4 million in cash at June 30, 2026, and said upfront proceeds from its July offering extend its runway into the first quarter of 2027. The company also regained NYSE American compliance on August 3, 2026.
3. 2026-08-03 Listings [AEON regains NYSE American compliance after July offering](https://aibio.space/news/aeon-regains-nyse-american-compliance-after-july-offering/) NYSE Regulation confirmed that AEON resolved the stockholders' equity deficiencies it had reported, after an offering that closed on July 15, 2026. The company expects the below-compliance indicator to be removed from its trading symbol.
4. 2026-07-23 Financings [AEON reports partial over-allotment exercise in July offering](https://aibio.space/news/aeon-reports-partial-allotment-exercise-july-offering/) The underwriters bought 4,696,102 additional shares on July 23, 2026, for about $1.5 million in gross proceeds. Lake Street Capital Markets, LLC acted as representative of the underwriters.
5. 2026-07-13 Financings [AEON prices upsized $13.75 million offering with milestone warrants](https://aibio.space/news/aeon-prices-upsized-13-75-million-offering-milestone-warrants/) The offering was priced at $0.3221 per share and accompanying warrants. Lake Street Capital Markets, LLC is sole bookrunner, and Laidlaw & Company (UK) Ltd. is lead manager.
6. 2026-04-03 Listings [AEON Biopharma receives additional NYSE American notice over stockholders' equity](https://aibio.space/news/aeon-biopharma-receives-additional-nyse-american-notice-stockholders/) The notice cites a stockholders' deficit of approximately $55 million as of December 31, 2025. AEON keeps its listing and has until August 3, 2026 to regain compliance.
7. 2026-01-21 Financings [AEON Biopharma completes Daewoong note exchange, issuing 11,918,380 shares and a $1,500,000 note](https://aibio.space/news/aeon-biopharma-completes-daewoong-note-exchange-issuing-11-918-380/) AEON Biopharma exchanged its senior secured convertible notes held by Daewoong for new shares, pre-funded warrants and a smaller $1,500,000 note after stockholders approved the deal on January 21, 2026. The swap adds dilution, and the second closing of its private placement is still pending.
8. 2025-04-25 Listings [NYSE American accepts AEON Biopharma plan, sets August 3, 2026 deadline](https://aibio.space/news/nyse-american-accepts-aeon-biopharma-plan-sets-august-3-2026-deadline/) NYSE American accepted AEON Biopharma's plan to regain compliance with three continued listing standards and gave the company until August 3, 2026. The 8-K does not say which financial measures the company missed, and the company's migraine trials failed their primary endpoints.
9. 2025-01-06 Financings [AEON Biopharma prices $20.0 million offering of units at $0.50 each](https://aibio.space/news/aeon-biopharma-prices-20-0-million-offering-units-0-50-each/) AEON Biopharma priced 40,000,000 units at $0.50 each for about $20.0 million gross, with Aegis Capital Corp. as sole book-running manager. Each unit carries two warrants that cannot be exercised until stockholders approve them, and their exercise price can reset lower.

## AEON Biopharma at a glance

- **Ticker**: AEON

- **Listing**: AMEX

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.4 million

### Related companies

- [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP
- [Travere Therapeutics](https://aibio.space/companies/travere-therapeutics/) NASDAQ: TVTX
- [Abeona Therapeutics](https://aibio.space/companies/abeona-therapeutics/) NASDAQ: ABEO
- [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) NASDAQ: FBIO
- [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD
- [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) NASDAQ: OVID
- [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) AMEX: PLX
- [ProtoKinetix](https://aibio.space/companies/protokinetix/) OTC: PKTX

### Also on AMEX

- [Perspective Therapeutics](https://aibio.space/companies/perspective-therapeutics/) CATX
- [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) KAPA
- [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) NSRX
- [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) RGNT
- [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) APUS
- [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) ARMP

## What AEON Biopharma does

AEON Biopharma, Inc. is a biopharmaceutical company developing ABP-450, a botulinum toxin complex, as a biosimilar to Botox (onabotulinumtoxinA) for therapeutic indications. The company plans to pursue United States approval through a biologics license application under Section 351(k) of the Public Health Service Act. It holds exclusive development and commercialization rights for ABP-450 in therapeutic indications across the United States, Canada, the European Union, the United Kingdom and certain other territories. ABP-450 is manufactured by Daewoong Pharmaceutical Co., Ltd. and is approved as a biosimilar in Mexico, India and Philippines. In the United States, the same toxin is approved for aesthetic use under the brand name Jeuveau, marketed by Evolus, Inc. The company met with the FDA in January 2026 to discuss its analytical similarity strategy and plans to complete most of its analytical comparability program in 2026. The company estimates the therapeutic botulinum toxin market at least $3.3 billion in 2025.

| Product or program | What it is | Stage |
|---|---|---|
| ABP-450 | Botulinum toxin complex as a biosimilar to Botox for therapeutic indications | Analytical similarity program ongoing under the 351(k) pathway |

Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/aeon-20251231x10k.htm).

## AEON Biopharma annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) | [$14.2 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) |
| Net income (loss) | [-$39.2 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) | [$42.0 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) |
| Cash from operations | [-$17.3 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) | [-$20.3 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) |
| Cash and equivalents | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000062/) | [$13,000](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000019/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about AEON Biopharma

Did AEON Biopharma do a reverse stock split?

Our latest story on this, dated Oct 26, 2026: "AEON Biopharma seeks approval for a reverse split of up to 1-for-100". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aeon-biopharma-seeks-approval-reverse-split-up-1-100/).

Has AEON Biopharma raised money recently?

Our latest story on this, dated Aug 12, 2026: "AEON reports second-quarter 2026 results and a $15.3 million financing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aeon-reports-second-quarter-2026-results-15-3-million-financing/).

Has AEON Biopharma sold convertible notes?

Our latest story on this, dated Jan 21, 2026: "AEON Biopharma completes Daewoong note exchange, issuing 11,918,380 shares and a $1,500,000 note". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aeon-biopharma-completes-daewoong-note-exchange-issuing-11-918-380/).

What is the ticker symbol of AEON Biopharma?

AEON Biopharma, Inc. trades under the ticker AEON on AMEX.

Where is AEON Biopharma listed?

AEON Biopharma, Inc. is listed on AMEX.

What is the SEC CIK of AEON Biopharma?

The SEC Central Index Key (CIK) for AEON Biopharma, Inc. is 1837607. Its filings are on SEC EDGAR.

How many shares does AEON Biopharma have outstanding?

49,882,790 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is AEON Biopharma listed under?

Our directory records AEON Biopharma, Inc. under United States.

What does AEON Biopharma do?

Our directory classifies AEON Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of AEON Biopharma?

The ISIN recorded for AEON Biopharma, Inc. is US00791X2099.

Does aibio.space cover AEON Biopharma?

aibio.space lists AEON Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is AEON Biopharma incorporated?

SEC records list its state or country of incorporation as DE.

What does AEON Biopharma develop?

AEON Biopharma, Inc. is a biopharmaceutical company developing ABP-450, a botulinum toxin complex, as a biosimilar to Botox (onabotulinumtoxinA) for therapeutic indications. The company plans to pursue United States approval through a biologics license application under Section 351(k) of the Public Health Service Act.

What is ABP-450 from AEON Biopharma?

ABP-450: Botulinum toxin complex as a biosimilar to Botox for therapeutic indications Stage: Analytical similarity program ongoing under the 351(k) pathway.

Is AEON Biopharma profitable?

AEON Biopharma, Inc. reported a net loss of $39.2 million for the fiscal year ended Dec 31, 2025, and used $17.3 million of cash in operations, per its annual report to the SEC.

## Investor discussion: AEON Biopharma

Members talk about AEON Biopharma (AEON). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at AEON Biopharma, newest first. Each line links the filing it comes from.

1. 2026-10-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000074/aeon-20261026xdef14a.htm)
2. 2026-10-13 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000068/aeon-20261013xpre14a.htm)
3. 2026-08-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812xex99d1.htm)
4. 2026-08-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/aeon-20260803xex99d1.htm)
5. 2026-07-08 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000110465926081860/tm2615250-3_s1.htm)
6. 2026-04-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/aeon-20260331xex99d1.htm)
7. 2026-01-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,5.07,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/aeon-20260121xex99d1.htm)
8. 2025-12-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000104/aeon-20251229xdef14a.htm)
9. 2025-12-19 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000099/aeon-20251219xpre14a.htm)
10. 2025-12-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/aeon-20251215xex99.htm)
11. 2025-12-04 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000088/aeon-20251204xex99.htm)
12. 2025-11-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000072/aeon-20251112x8k.htm)
13. 2025-06-16 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000110465925059840/tm2517816d1_424b5.htm)
14. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000032/aeon-20250422x8k.htm)
15. 2025-02-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000013/aeon-20250224xex99.htm)
16. 2025-02-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/aeon-20250203xex99.htm)
17. 2025-01-23 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000007/aeon-20250224xdef14a.htm)
18. 2025-01-13 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000005/aeon-20250224xpre14a.htm)
19. 2025-01-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1837607/000110465925000991/tm2432042-1_424b5.htm)
20. 2025-01-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/tm2432042d2_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:AEON on TradingView](https://www.tradingview.com/symbols/AMEX-AEON/).

## SEC filings and registration

- **SEC name**: AEON Biopharma, Inc.

- **CIK**: 1837607

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: AEON (NYSE)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 130 VANTIS DRIVE, ALISO VIEJO, CA, 92656

- **Phone**: (949) 354-6499

- **Shares outstanding**: 49,882,790 as of 2026-08-06 (10-Q filed 2026-08-12)

- **Former names**: Priveterra Acquisition Corp.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/aeon-20260930x8k.htm) filed 2026-09-30
- [10-Q](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000062/aeon-20260630x10q.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812x8k.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/aeon-20260803x8k.htm) filed 2026-08-03
- [8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000055/aeon-20260723x8k.htm) filed 2026-07-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000052/aeon-20260713x8k.htm) filed 2026-07-15
- [S-1](https://www.sec.gov/Archives/edgar/data/1837607/000110465926081860/tm2615250-3_s1.htm) filed 2026-07-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000046/aeon-20260617x8k.htm) filed 2026-06-17

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001837607), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

AEON Biopharma, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker AEON, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: AEON Biopharma, Inc.

- **Ticker**: AEON

- **Listing**: AMEX

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US00791X2099

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-AEON/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/aeon-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "AEON Biopharma (AEON) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/aeon-biopharma/